Aptevo Therapeutics Stock Forum

$Aptevo Therapeutics (APVO.US)$ go go go

$Aptevo Therapeutics (APVO.US)$
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Aptevo Therapeutics (NASDAQ: APVO) reports promising early results from its RAINIER trial, where the first patient treated with mipletamig achieved a 90% reduction in leukemic blasts within 30 days.
The trial evaluates mipletamig as a frontline therapy for Ac...

$Aptevo Therapeutics (APVO.US)$ time to load now

$Aptevo Therapeutics (APVO.US)$ First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Accesswire· 4 mins ago
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved patient outcomes
Favorable early ...

$Aptevo Therapeutics (APVO.US)$ great news

$Aptevo Therapeutics (APVO.US)$ First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
2 MINUTES AGO, 8:05 AM EST
VIA ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient re...

$Aptevo Therapeutics (APVO.US)$
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics (APVO) and Alligator Bioscience reported positive preliminary data from their Phase 1 trial of ALG.APV-527, a first-in-class bispecific antibody for solid tumors. The trial met key endpoints for safety, tolerability, and biological activity. 56% of evaluable patients (9/16) achieved stable disease, including a colon cancer patient st...

$Aptevo Therapeutics (APVO.US)$ go go go...

$Aptevo Therapeutics (APVO.US)$ 回后买上涨 lets gooo

$Aptevo Therapeutics (APVO.US)$ $1 today!